DK1163002T3 - Polykationiske kulhydrater som immunstimulanser i vacciner - Google Patents

Polykationiske kulhydrater som immunstimulanser i vacciner

Info

Publication number
DK1163002T3
DK1163002T3 DK00912788T DK00912788T DK1163002T3 DK 1163002 T3 DK1163002 T3 DK 1163002T3 DK 00912788 T DK00912788 T DK 00912788T DK 00912788 T DK00912788 T DK 00912788T DK 1163002 T3 DK1163002 T3 DK 1163002T3
Authority
DK
Denmark
Prior art keywords
vaccines
polycationic
carbohydrates
immune stimulants
polycationic carbohydrates
Prior art date
Application number
DK00912788T
Other languages
Danish (da)
English (en)
Inventor
Satyanarayana Somavarapu
Ethel Diane Williamson
Hazire Oya Alpar
James Edward Eyles
Leslie William James Baillie
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906694.6A external-priority patent/GB9906694D0/en
Priority claimed from GBGB9906696.1A external-priority patent/GB9906696D0/en
Application filed by Secr Defence filed Critical Secr Defence
Application granted granted Critical
Publication of DK1163002T3 publication Critical patent/DK1163002T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00912788T 1999-03-24 2000-03-23 Polykationiske kulhydrater som immunstimulanser i vacciner DK1163002T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9906694.6A GB9906694D0 (en) 1999-03-24 1999-03-24 Vaccine composition
GBGB9906696.1A GB9906696D0 (en) 1999-03-24 1999-03-24 Vaccine composition
PCT/GB2000/001118 WO2000056362A2 (en) 1999-03-24 2000-03-23 Polycationic carbohydrates as immunostimulants in vaccines

Publications (1)

Publication Number Publication Date
DK1163002T3 true DK1163002T3 (da) 2009-01-19

Family

ID=26315329

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00912788T DK1163002T3 (da) 1999-03-24 2000-03-23 Polykationiske kulhydrater som immunstimulanser i vacciner

Country Status (11)

Country Link
US (1) US20080057083A1 (de)
EP (2) EP1163002B1 (de)
JP (3) JP2002540076A (de)
AT (1) ATE403436T1 (de)
AU (2) AU755502C (de)
CA (2) CA2366216C (de)
DE (1) DE60039754D1 (de)
DK (1) DK1163002T3 (de)
ES (1) ES2311451T3 (de)
NZ (1) NZ514323A (de)
WO (2) WO2000056361A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1265598B1 (de) * 2000-03-22 2006-08-02 The Secretary of State for Defence Arzneimittel zur verabreichung an schleimhäute
AU2001276831A1 (en) 2000-06-22 2002-01-02 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
AU2001273034A1 (en) 2000-06-26 2002-01-08 Rxkinetix, Inc. Composition for delivery of hematopoietic growth factor
WO2003005952A2 (en) * 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
DE60223037T2 (de) 2001-08-16 2008-07-24 Cmp Therapeutics Ltd. Chitin-mikropartikel und ihre medizinische verwendung
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1432402B1 (de) * 2001-10-03 2006-11-22 Celator Pharmaceuticals, Inc. Zusammensetzungen zur verabreichung von arzneimittelkombinationen
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0300885D0 (en) * 2003-01-15 2003-02-12 Secr Defence Pharmaceutical composition
JP2006516609A (ja) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ 粘膜髄膜炎菌性ワクチン
EP1594536B1 (de) * 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Adjuvante influenza-vakzine
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
JP4669665B2 (ja) * 2004-04-12 2011-04-13 正彦 阿部 細胞毒性のないポリカチオン修飾リポソームおよびその製造方法
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
WO2007100699A2 (en) * 2006-02-24 2007-09-07 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
WO2008041703A1 (fr) * 2006-10-02 2008-04-10 Osaka University Adjuvant pour vaccin contre la grippe et vaccin contre la grippe
JP5297009B2 (ja) * 2007-07-24 2013-09-25 大日精化工業株式会社 免疫アジュバント水溶液
MY148321A (en) * 2007-10-02 2013-03-29 Malaysian Palm Oil Board Mpob Vitamin e supplementation to tetanus toxoid
GB0721937D0 (en) 2007-11-08 2007-12-19 Secr Defence Rodenticide
WO2010017330A1 (en) * 2008-08-06 2010-02-11 Novartis Ag Microparticles for use in immunogenic compositions
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
AU2012255878B2 (en) * 2011-05-18 2016-05-12 Matrivax Research & Development Corporation Protein matrix vaccine compositions including polycations
US10500283B2 (en) 2011-05-30 2019-12-10 National Institute Of Immunology Vaccine composition capable of inducing memory antibody response from single point immunization
CN107200788B (zh) * 2017-05-11 2020-04-14 暨南大学 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用
CN107899021A (zh) * 2017-11-06 2018-04-13 扬州大学 一种表面修饰s‑层蛋白的壳聚糖微球、制备及应用
KR102384808B1 (ko) * 2018-12-20 2022-04-08 주식회사 스킨메드 키토산으로 코팅된 나노 캡슐 및 이의 용도
EP3960203A1 (de) 2020-08-25 2022-03-02 Université de Liège Komplexe zur abgabe von proteinischen wirkstoffen

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
GB1290141A (de) * 1968-05-31 1972-09-20
FR2306684A1 (fr) * 1975-04-11 1976-11-05 Crinex Lab Nouvelle composition a action immunostimulante
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
ZA881694B (en) * 1987-03-17 1988-09-06 Akzo N.V. Adjuvant mixture
EP0382271B1 (de) * 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocole als Impfstoffadjuvans
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DE4004430A1 (de) * 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
BR9405996A (pt) * 1993-03-11 1995-12-19 Secretech Inc Mucoadesivos poliméricos na distribuição de imunógenos em superfícies mucosais
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
AU710181B2 (en) * 1995-03-13 1999-09-16 Secretary Of State For Defence, The Vaccines for plague
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
DE19603649A1 (de) * 1996-02-01 1997-08-07 Werner Lubitz Rekombinante Expression von S-Layer-Proteinen
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB9810126D0 (de) * 1998-05-13 1998-07-08 Glaxo Group Ltd
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US20030171258A1 (en) * 1999-03-24 2003-09-11 Alpar Hazire Oya Particle based vaccine composition
US20020103165A1 (en) * 2000-02-29 2002-08-01 Alliance Pharmaceutical Corp., Engineered spray-dried lipid-based microparticles for cellular targeting
EP1265598B1 (de) * 2000-03-22 2006-08-02 The Secretary of State for Defence Arzneimittel zur verabreichung an schleimhäute
GB0300885D0 (en) * 2003-01-15 2003-02-12 Secr Defence Pharmaceutical composition

Also Published As

Publication number Publication date
JP2002540077A (ja) 2002-11-26
EP1163001A2 (de) 2001-12-19
JP2012031186A (ja) 2012-02-16
WO2000056361A3 (en) 2001-03-01
US20080057083A1 (en) 2008-03-06
DE60039754D1 (de) 2008-09-18
CA2366216C (en) 2012-10-23
NZ514323A (en) 2003-03-28
JP5124066B2 (ja) 2013-01-23
AU3442400A (en) 2000-10-09
CA2366908A1 (en) 2000-09-28
AU755502C (en) 2003-08-14
ES2311451T3 (es) 2009-02-16
WO2000056362A2 (en) 2000-09-28
WO2000056361A2 (en) 2000-09-28
AU3443500A (en) 2000-10-09
AU762078B2 (en) 2003-06-19
EP1163002A2 (de) 2001-12-19
ATE403436T1 (de) 2008-08-15
WO2000056362A3 (en) 2001-02-01
EP1163002B1 (de) 2008-08-06
CA2366216A1 (en) 2000-09-28
JP2002540076A (ja) 2002-11-26
AU755502B2 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
DK1163002T3 (da) Polykationiske kulhydrater som immunstimulanser i vacciner
PL351893A1 (en) Vaccines
GB0025577D0 (en) Vaccine
MXPA04005865A (es) Suministro de aminoglucosidos a los pulmones.
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
MY129263A (en) Vaccine composition
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
EP1352895A3 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
HUP0401606A2 (hu) West Nile vakcina
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
EP0979080A4 (de) Verfahren zur modulation der immunreaktion in einem infektierten säugetier mittels transmukosales eingeben eines modulationsmittel
EP1471936A4 (de) Hiv-vakzine und anwendungsverfahren
MY127452A (en) Vaccines.
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
EP1303300A4 (de) Zusammensetzungen und methoden zur behandlung von candidosen
EP1411956B8 (de) Verwendung von übersulfatierten polysacchariden als hiv-hemmer
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2000057919A3 (en) Lipid-based artificial particles inducing cell-mediated immunity
HUP0302371A2 (hu) Béta-blokkolót és adott esetben koleszterinszint-csökkentőt tartalmazó új gyógyszerkészítmény
UA38352A (uk) Засіб для лікувальних ванн
GEU2001787Y (en) Medicinal Tea
UA29558C2 (uk) Препарат для лікування бронхіальної астми " еуфілін-н 200"